Diabetic FootPAIDNCT04085705
The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers (PAID Study)
An observational study of Diabetic Foot and Contact Allergy, run by Rijnstate Hospital at 1 site in Netherlands.
Trial summary
Rationale: Foot ulcers among diabetics are common. The presence of a contact allergy limits the healing process. Contact allergies for wound dressings are common among patients with ulcers caused by venous insufficiency but less is known about contact allergies in diabetic patients with ulcers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Diabetic Foot, Contact Allergy
- What is being tested?
- PATCH test
- How many people
- 139 participants
- Where
- 1 siteNetherlands
- Study dates
- 17 Sep 2019to Dec 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population are high risk diabetic patients with a foot ulcer visiting the multidisciplinary consultation hour for diabetics at the clinic. Diabetic patients are patients diagnosed with type 1 or type 2 diabetes.
Who may be able to join
- Age of 18 years or older;
- Diagnosed with type 1 or 2 diabetes mellitus;
- Diagnosed with diabetic foot ulcer;
- Provided written informed consent.
Who cannot join
- Patient unwilling or unlikely to comply with the study procedures
- Patient receiving systemic corticosteroid therapy during PATCH testing (patient should stop with corticosteroid therapy three days before PATCH testing, and may start when testing and reading is done)
- Patient receiving antihistaminic therapy during PATCH testing (patient should stop with antihistaminic therapy three days before PATCH testing, and may start when testing and reading is done)
Trial locations and contacts
1 site in 1 country.
Netherlands1 site, 1 recruiting
- Recruiting
Rijnstate
Arnhem, Gelderland, 6800 TA
Birgitte Visch, MD, 0031 (0)88-0055081,, bvisch@rijnstate.nl
About this study
Official title: The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers
Rationale: Foot ulcers among diabetics are common. The presence of a contact allergy limits the healing process. Contact allergies for wound dressings are common among patients with ulcers caused by venous insufficiency but less is known about contact allergies in diabetic patients with ulcers.
Objective: To determine the prevalence of contact allergies for wound dressings in patients with diabetic foot ulcers.
Read more
Study design: A prospective multicenter study.
Study population: Patients (n=139) with diabetic foot ulcers caused by type 1 or 2 diabetes mellitus treated at Rijnstate Hospital Arnhem, the Netherlands.
Main study parameters/endpoints: The primary study parameter is the presence of contact allergies for wound dressings.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: An allergy test is standard procedure at Rijnstate Hospital, there is no direct technique-related burden or risk for the patient. In addition, wound dressings can be adjusted in patients where a contact allergy is determined which will benefit the prognosis of these patients. The data of this study will give insight in the prevalence of contact allergies for wound dressings in patients with diabetic foot ulcers.
Read the detailed description
Foot ulcers among diabetics are common. In 2015, around 20,000 patients in the Netherlands had a diabetic foot ulcer.1 A study using data from Dutch general practices found a prevalence rate of 0.50% and a 4-year prevalence rate of 2.85%.2 For Europe, Zhang et al. estimated a pooled prevalence of 5.1% (95%CI: 4.1-6.0%).3 Prevalence rates increase with age.
The underlying mechanism of diabetic foot ulcers is most often solely neuropathy (60 to 70%), 15 to 20% have peripheral artery disease (PAD) only, and 15 to 20% have a mixture of both.4 Diabetic foot is more prevalent in males and more prevalent in type 2 diabetes than in type 1 diabetes3. Ulcers in patients without diabetes are mostly caused by venous insufficiency.5
Ulcers have a slow healing tendency. Around 15 percent of diabetic patients with an ulcer eventually have to amputate (a part of) the leg.1 Good wound care is therefore important. However, wound care can be delayed in the presence of a contact allergy. Contact allergy (synonym for contact sensitivity) is defined as an altered immune status of an individual induced by a particular sensitizing substance, a contact allergen. An individual in whom contact allergy has been induced will develop a secondary immune response if there is skin exposure to the same (or cross-reacting) allergen. This process is called elicitation, and will manifest as allergic contact dermatitis (type IV hypersensitivity).6 Allergic contact dermatitis, also termed allergic contact eczema, is defined as an inflammatory skin reaction caused by direct contact with noxious agents in the environment as a result of contact allergy.
Among patients with venous leg ulcers contact allergies is seen in around 50 percent of which 10-20% for wound dressings.7-10 The prevalence of contact allergies is getting higher and also increasing with the duration of the ulcer. 8,10 Wound dressings can cause allergic contact eczema (allergic contact dermatitis).
At present, the prevalence of contact allergies for wound dressings in diabetic patients with foot ulcers is unknown. With this study we want to gain insight in the prevalence of contact allergies in patients with diabetic foot ulcers and investigate if the prevalence of contact allergies among diabetic patients is as high as the prevalence in patients with venous leg ulcers.
Objective of the study:
The primary objective of this study is to determine the prevalence of contact allergies in patients with diabetic foot ulcers.
Study design:
This is a prospective, multi-centre study.
Study population:
The study population are high risk diabetic patients with a foot ulcer visiting the multidisciplinary consultation hour for diabetics at the clinic.
Diabetic patients are patients diagnosed with type 1 or type 2 diabetes.
Primary study parameters/outcome of the study:
The presence of contact allergy for wound dressings
Secundary study parameters/outcome of the study (if applicable):
The following factors will be gathered at baseline:
- Age
- Gender
- Diabetes type
- Duration of diabetes
- Medication use
- Ulcer characteristics like type, size, duration, progress (TEXAS classification)
- Number of past foot ulcers
- Duration of past foot ulcers
- Known allergies or atopy constitution
- Presence of allergic contact dermatitis around the wound
- Doses corticosteroid or antihistaminic therapy (not during PATCH testing)
- History of eczema
Parameters to define if there are other mechanisms besides diabetics underlying the ulcer:
- Ankle brachial index , toe pressure measurement or Transcutaneous oxygen pressure (TcPo2)
- Venous insufficiency which is measured by a venous duplex, if applicable
Parameters related with contact allergy or parameters that can influence the development of a contact allergy:
- Known allergy. If yes, which allergy/allergies?
- Duration of current ulcus cruris
- Number of past ulcers
- Treatment with wound dressing(s) current episode:
- Duration of ulcer
- Treatment with wound dressing(s) prior episode(s)
- Prevalence of allergic contact dermatitis
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):
Not applicable
- Conditions
- Diabetic Foot, Contact Allergy
- Being tested
- PATCH test
- Keywords
- Wound Dressing
- Medical subject headings
- Diabetic Foot, Dermatitis, Allergic Contact
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
PATCH testDiagnostic test
The PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined.
| Study group | Role | What they receive |
|---|---|---|
| Patients with diabetic foot ulcers | All patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings. Receives: Diagnostic Test: PATCH test |
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of contact allergy for wound dressings
The presence of contact allergy for wound dressings
Measured: 3 days after application of PATCH test
Secondary outcomes (1)
Presence of eczema
Presence of eczema/dermatitis
Measured: Collected at baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2019
- Study start17 Sep 2019
- Primary completionDec 2022 (estimated)
- Study completionDec 2022 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Diabetic FootStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 139 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Rijnstate Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Birgitte Visch MD, Rijnstate Hospital
- Investigators
- Birgitte Visch, MD, Principal investigator, Rijnstate
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04085705
- Sponsor's protocol ID
- PAID study
- Acronym
- PAID
- Status last verified
- Oct 2021
- First submitted
- 9 Sep 2019
- Last updated
- 18 Oct 2021
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Visch BM, Veen DV, Smeets L, Toeter R, Bon AV, Romijn D. The Prevalence of Contact Allergies for Wound Dressings in Patients With Diabetic Foot Ulcers (PAID Study), an Observational Prospective Trial. Int J Low Extrem Wounds. 2026 Sep;25(3):1038-1043. doi: 10.1177/15347346251332028. Epub 2025 Apr 10.
PubMed 40208179
Study at a glance
From the registry record, last updated by the sponsor on 18 Oct 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Prevalence of Contact Allergies for Wound Dressings In Patients With Diabetic Foot Ulcers
- ClinicalTrials.gov ID
- NCT04085705
- Acronym / sponsor ID
- PAID / PAID study
- Conditions
- Diabetic Foot, Contact Allergy
- Keywords
- Wound Dressing
- Study type
- Observational
- Recruitment status
- Unknown status
- Enrolment
- 139 participants (estimated)
- Lead sponsor
- Rijnstate HospitalUniversity, hospital or other
- Study start
- 17 Sep 2019 (actual)
- Primary completion
- Dec 2022 (estimated)
- Study completion
- Dec 2022 (estimated)
- First posted
- 11 Sep 2019 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale: Foot ulcers among diabetics are common. The presence of a contact allergy limits the healing process. Contact allergies for wound dressings are common among patients with ulcers caused by venous insufficiency but less is known about contact allergies in diabetic patients with ulcers.
Objective: To determine the prevalence of contact allergies for wound dressings in patients with diabetic foot ulcers.
Study design: A prospective multicenter study.
Study population: Patients (n=139) with diabetic foot ulcers caused by type 1 or 2 diabetes mellitus treated at Rijnstate Hospital Arnhem, the Netherlands.
Main study parameters/endpoints: The primary study parameter is the presence of contact allergies for wound dressings.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: An allergy test is standard procedure at Rijnstate Hospital, there is no direct technique-related burden or risk for the patient. In addition, wound dressings can be adjusted in patients where a contact allergy is determined which will benefit the prognosis of these patients. The data of this study will give insight in the prevalence of contact allergies for wound dressings in patients with diabetic foot ulcers.
Detailed description
Foot ulcers among diabetics are common. In 2015, around 20,000 patients in the Netherlands had a diabetic foot ulcer.1 A study using data from Dutch general practices found a prevalence rate of 0.50% and a 4-year prevalence rate of 2.85%.2 For Europe, Zhang et al. estimated a pooled prevalence of 5.1% (95%CI: 4.1-6.0%).3 Prevalence rates increase with age.
The underlying mechanism of diabetic foot ulcers is most often solely neuropathy (60 to 70%), 15 to 20% have peripheral artery disease (PAD) only, and 15 to 20% have a mixture of both.4 Diabetic foot is more prevalent in males and more prevalent in type 2 diabetes than in type 1 diabetes3. Ulcers in patients without diabetes are mostly caused by venous insufficiency.5
Ulcers have a slow healing tendency. Around 15 percent of diabetic patients with an ulcer eventually have to amputate (a part of) the leg.1 Good wound care is therefore important. However, wound care can be delayed in the presence of a contact allergy. Contact allergy (synonym for contact sensitivity) is defined as an altered immune status of an individual induced by a particular sensitizing substance, a contact allergen. An individual in whom contact allergy has been induced will develop a secondary immune response if there is skin exposure to the same (or cross-reacting) allergen. This process is called elicitation, and will manifest as allergic contact dermatitis (type IV hypersensitivity).6 Allergic contact dermatitis, also termed allergic contact eczema, is defined as an inflammatory skin reaction caused by direct contact with noxious agents in the environment as a result of contact allergy.
Among patients with venous leg ulcers contact allergies is seen in around 50 percent of which 10-20% for wound dressings.7-10 The prevalence of contact allergies is getting higher and also increasing with the duration of the ulcer. 8,10 Wound dressings can cause allergic contact eczema (allergic contact dermatitis).
At present, the prevalence of contact allergies for wound dressings in diabetic patients with foot ulcers is unknown. With this study we want to gain insight in the prevalence of contact allergies in patients with diabetic foot ulcers and investigate if the prevalence of contact allergies among diabetic patients is as high as the prevalence in patients with venous leg ulcers.
Objective of the study:
The primary objective of this study is to determine the prevalence of contact allergies in patients with diabetic foot ulcers.
Study design:
This is a prospective, multi-centre study.
Study population:
The study population are high risk diabetic patients with a foot ulcer visiting the multidisciplinary consultation hour for diabetics at the clinic.
Diabetic patients are patients diagnosed with type 1 or type 2 diabetes.
Primary study parameters/outcome of the study:
The presence of contact allergy for wound dressings
Secundary study parameters/outcome of the study (if applicable):
The following factors will be gathered at baseline:
- Age
- Gender
- Diabetes type
- Duration of diabetes
- Medication use
- Ulcer characteristics like type, size, duration, progress (TEXAS classification)
- Number of past foot ulcers
- Duration of past foot ulcers
- Known allergies or atopy constitution
- Presence of allergic contact dermatitis around the wound
- Doses corticosteroid or antihistaminic therapy (not during PATCH testing)
- History of eczema
Parameters to define if there are other mechanisms besides diabetics underlying the ulcer:
- Ankle brachial index , toe pressure measurement or Transcutaneous oxygen pressure (TcPo2)
- Venous insufficiency which is measured by a venous duplex, if applicable
Parameters related with contact allergy or parameters that can influence the development of a contact allergy:
- Known allergy. If yes, which allergy/allergies?
- Duration of current ulcus cruris
- Number of past ulcers
- Treatment with wound dressing(s) current episode:
- Duration of ulcer
- Treatment with wound dressing(s) prior episode(s)
- Prevalence of allergic contact dermatitis
Nature and extent of the burden and risks associated with participation, benefit and group relatedness (if applicable):
Not applicable
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Patients with diabetic foot ulcers | – | Diagnostic Test: PATCH testAll patients with diabetic foot ulcers will undergo a PATCH test to determine the prevalence of contact allergies against wound dressings. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population are high risk diabetic patients with a foot ulcer visiting the multidisciplinary consultation hour for diabetics at the clinic. Diabetic patients are patients diagnosed with type 1 or type 2 diabetes.
Key inclusion criteria (4 listed)
- Age of 18 years or older;
- Diagnosed with type 1 or 2 diabetes mellitus;
- Diagnosed with diabetic foot ulcer;
- Provided written informed consent.
Key exclusion criteria (3 listed)
- Patient unwilling or unlikely to comply with the study procedures
- Patient receiving systemic corticosteroid therapy during PATCH testing (patient should stop with corticosteroid therapy three days before PATCH testing, and may start when testing and reading is done)
- Patient receiving antihistaminic therapy during PATCH testing (patient should stop with antihistaminic therapy three days before PATCH testing, and may start when testing and reading is done)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| PATCH testThe PATCH test is a method used to determine whether a specific substance causes allergic inflammation of a patient's skin, in this case contact allergy for wound dressings. Two days after PATCH test is applied, the patches are removed. The next day, the presence of a contact allergy is determined. | Diagnostic test | Patients with diabetic foot ulcers |
Primary outcome
Presence of contact allergy for wound dressings
Time frame: 3 days after application of PATCH test
The presence of contact allergy for wound dressings
1 secondary outcome
Presence of eczema
Time frame: Collected at baseline
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Oct 2021.
- Derived from this study: PubMed 40208179Visch BM, Veen DV, Smeets L, Toeter R, Bon AV, Romijn D. The Prevalence of Contact Allergies for Wound Dressings in Patients With Diabetic Foot Ulcers (PAID Study), an Observational Prospective Trial. Int J Low Extrem Wounds. 2026 Sep;25(3):1038-1043. doi: 10.1177/15347346251332028. Epub 2025 Apr 10.
Related trials for Diabetic Foot
Recruiting
PAW-Hydrogel for Chronic Wound Healing
Diabetic Foot Ulcer (DFU), Pressure Ulcer (PU)
Active, not recruiting
Wearable Insoles for Recurrent Diabetic Ulcer Prevention
Diabetes, Peripheral Neuropathy
Active, not recruiting
Evaluation of Personalized Nutritional Intervention on Wound Healing of Cutaneous Ulcers in Diabetics
Foot, Diabetic
Not yet recruiting
Efficacy Evaluation of Turmeric-Derived Nanoparticle Hydrogel for the Treatment of Diabetic Foot Ulcer Wounds
Diabete Mellitus
Not yet recruiting
Better Care Closer to Home: Enhancing Primary and Community Care
Diabetic Foot Disease, Recurrence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Birgitte Visch, MD principal investigator
Rijnstate
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Diabetic Foot and Contact Allergy, run by Rijnstate Hospital at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Birgitte Visch, MD (0031 (0)88-0055081, bvisch@rijnstate.nl), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of contact allergy for wound dressings (time frame: 3 days after application of PATCH test). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04085705, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Oct 2021.